TY - JOUR
AU1 - Wilson, Alexandra
AU2 - Sharp, Margaret
AU3 - Koropchak, Celine M.
AU4 - Ting, Shirley F.
AU5 - Arvin, Ann M.
AB - Bone marrow transplant (BMT) recipients were evaluated for subclinical varicella-zoster virus (VZV) viremia and symptoms of herpes zoster after transplantation. Viremia was demonstrated by testing peripheral blood mononuclear cells using polymerase chain reaction and was documented in 19% of 37 patients. When reactivation was defined as herpes zoster and/or subclinical VZV viremia, 41% of VZV-seropositive BMT recipients experienced VZV reactivation. None of 12 patients tested before VZV reactivation had T lymphocyte proliferation to VZV antigen (mean stimulation index, 1.0 ± 0.42 [SD] at < 100 days; 12.0 ± 6.03 at > 100 days [P = .003]). Among patients tested at > 100 days, 5 (63%) of 8 with detectable T cell proliferation had subclinical or clinical VZV reactivation compared with none of 6 who lacked VZV T cell responses. Recovery of VZV-specific cytotoxic T lymphocyte function was observed in 50% of BMT patients, but BMT recipients had significantly fewer circulating cytotoxic T lymphocytes that recognized VZV immediate early protein (P = .03) or glycoprotein I (P = .004) than did healthy VZV immune subjects. In vivo reexposure to VZV antigens due to subclinical VZV viremia or symptomatic VZV reactivation may explain the recovery ofvirus-specific T cell immunity after BMT.
TI - Subclinical Varicella-Zoster Virus Viremia, Herpes Zoster, and T Lymphocyte Immunity to Varicella-Zoster Viral Antigens after Bone Marrow Transplantation
JF - The Journal of Infectious Diseases
DO - 10.1093/infdis/165.1.119
DA - 1992-01-01
UR - https://www.deepdyve.com/lp/oxford-university-press/subclinical-varicella-zoster-virus-viremia-herpes-zoster-and-t-Q6f7rWn4xL
SP - 119
EP - 126
VL - 165
IS - 1
DP - DeepDyve
ER -